Home » Stocks » BHVN

Biohaven Pharmaceutical Holding Co. Ltd. (BHVN)

Stock Price: $72.74 USD -1.67 (-2.24%)
Updated Apr 19, 2021 11:36 AM EDT - Market open
Market Cap 4.81B
Revenue (ttm) 63.63M
Net Income (ttm) -766.80M
Shares Out 58.73M
EPS (ttm) -13.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $72.74
Previous Close $74.40
Change ($) -1.67
Change (%) -2.24%
Day's Open 73.32
Day's Range 72.74 - 74.32
Day's Volume 95,000
52-Week Range 37.92 - 100.77

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW HAVEN, Conn., April 13, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

6 days ago - PRNewsWire

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume.

1 week ago - Zacks Investment Research

NEW HAVEN, Conn., April 7, 2021 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd.

1 week ago - PRNewsWire

MOORESVILLE, N.C., April 6, 2021 /PRNewswire/ -- Rick Ware Racing announced today its partnership with Biohaven's Nurtec® ODT (rimegepant) and Nine Line Apparel to honor the nation's fallen service memb...

1 week ago - PRNewsWire

Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) has enrolled the first patient in a Phase 2/3 trial evaluating oral zavegepant for migraine's preventive treatment, triggering a milestone funding pay...

3 weeks ago - Benzinga

NEW HAVEN, Conn., March 29, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

3 weeks ago - PRNewsWire

Biohaven Pharmaceuticals CEO on how Nurtec migraine drug punches above its weight

YouTube video

Biohaven Pharmaceuticals CEO Vlad Coric said the company's digital-first and patient-focused strategy is giving it an edge against competitors in marketing the migraine drug Nurtec.

3 weeks ago - CNBC Television

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders took advantage of initial public offerings in the past week.

Other stocks mentioned: CPNG, KDP, GOCO, INVA, JOAN, MBIN, PFSI ...
4 weeks ago - Benzinga

NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

1 month ago - PRNewsWire

NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

1 month ago - PRNewsWire

Pharmaceutical stocks are a sector with unique success factors. One factor is developing blockbuster drugs.

Other stocks mentioned: ARGX, BMRN, MRTX, NVO, NVS
1 month ago - InvestorPlace

With the trading day halfway over, the broad markets were making yet another strong push.

Other stocks mentioned: ORCL, TSLA, AEP, CATB, ESPR, KDP, QSR ...
1 month ago - 24/7 Wall Street

NEW HAVEN, Conn., March 11, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

1 month ago - PRNewsWire

NEW HAVEN, Conn., March 10, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

1 month ago - PRNewsWire

NEW HAVEN, Conn., March 10, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

1 month ago - PRNewsWire

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

1 month ago - Zacks Investment Research

Agreement enables Biohaven to exercise option on up to three of Artizan's candidates for the treatment of inflammatory bowel disease

1 month ago - GlobeNewsWire

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -25.26% and 0.30%, respectively, for the quarter ended December 2020.

1 month ago - Zacks Investment Research

Shares of Biohaven Pharmaceutical (NYSE:BHVN) decreased 0.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 5.61% year over year to ($2.69), wh...

1 month ago - Benzinga

NEW HAVEN, Conn., March 1, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of ...

1 month ago - PRNewsWire

NEW HAVEN, Conn., Feb. 23, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product...

1 month ago - PRNewsWire

Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) hyperimmune globulin mimic developed with Biohaven's MATE platform has demonstrated functional binding and neutralization of the SARS-CoV-2 virus, i...

1 month ago - Benzinga

Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

NEW HAVEN, Conn., Feb. 22, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product...

1 month ago - PRNewsWire

NEW HAVEN, Conn., Feb. 8, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-st...

2 months ago - PRNewsWire

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Other stocks mentioned: AMPH, AQUA, BBDC, CFX, CRHM, GBT, HASI ...
2 months ago - Seeking Alpha

NEW HAVEN, Conn., Jan. 25, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-s...

2 months ago - PRNewsWire

Treating The Causes Of Alzheimer's Disease: The Case For Anavex 2-73

Other stocks mentioned: AVXL, BIIB, LLY, SAVA
2 months ago - Seeking Alpha

Biohaven Pharmaceuticals said Monday its experimental Alzheimer's treatment, known as troriluzole, failed during a midstage testing process. The news sent BHVN stock into a dive Tuesday.

2 months ago - Investors Business Daily

Biohaven (BHVN) announces preliminary data from a phase II/III AD study demonstrating troriluzole's failure to achieve statistical improvement in primary endpoints.

2 months ago - Zacks Investment Research

Alzheimer's claims another drug candidate.

3 months ago - The Motley Fool

MOORESVILLE, N.C., Jan. 18, 2021 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Cody Ware will pilot the Nurtec® ODT (rimegepant) #51 Chevrolet Camaro for Rick Ware Racing dur...

3 months ago - PRNewsWire

NEW HAVEN, Conn., Jan. 18, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that it has completed a focused analysis of the topline co-primary and key secon...

3 months ago - PRNewsWire

NEW HAVEN, Conn., Jan. 7, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") today announced the acquisition of the remaining 58% interest of Kle...

3 months ago - PRNewsWire

Biohaven (BHVN) initiates enrollment in a phase III study to evaluate troriluzole as adjunctive treatment for patients with obsessive-compulsive disorder.

3 months ago - Zacks Investment Research

NEW HAVEN, Conn., Jan. 4, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") today announced that it has commenced enrollment in a Phase 3 clinical trial assessi...

3 months ago - PRNewsWire

Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

NEW HAVEN, Conn., Dec. 16, 2020 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that The Lancet published the company's positive results from a Phase 3 clinica...

4 months ago - PRNewsWire

Biohaven is establishing a comprehensive suite of migraine medicines. The company has an exciting pipeline of interesting late stage products.

4 months ago - Seeking Alpha

MOORESVILLE, N.C., Dec. 2, 2020 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announces today that Nurtec™ ODT (rimegepant) will be the primary partner for the No. 51 Rick Ware Racing entry durin...

4 months ago - PRNewsWire

TOKYO and CAMBRIDGE, England, Dec. 1, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Ph...

4 months ago - PRNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other stocks mentioned: COTY, DHR, FL, BH, STOK
4 months ago - Benzinga

"I hope that in six months or so from now that we will be the first oral CGRP with the indication for the prevention of migraine," Biohaven CEO Vlad Coric said.

5 months ago - CNBC

Biohaven Pharmaceutical CEO on efforts to prevent migraine with oral CGRP

YouTube video

CEO Vlad Coric said Biohaven, a biotech firm with a new product to treat migraines, plans to have a drug that can prevent migraines in the next sixth months.

5 months ago - CNBC Television

NEW HAVEN, Conn., Nov. 16, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product...

5 months ago - PRNewsWire

NEW HAVEN, Conn., Nov. 11, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class ther...

5 months ago - PRNewsWire

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

5 months ago - Zacks Investment Research

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) CEO Vlad Coric on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

  Shares of Biohaven Pharmaceutical (NYSE:BHVN) traded flat in pre-market trading after the company reported Q3 results.

5 months ago - Benzinga

Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

5 months ago - Zacks Investment Research

About BHVN

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indi... [Read more...]

Industry
Biotechnology
IPO Date
May 4, 2017
CEO
Vlad Coric
Employees
825
Stock Exchange
NYSE
Ticker Symbol
BHVN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for BHVN stock is "Strong Buy." The 12-month stock price forecast is 101.91, which is an increase of 40.11% from the latest price.

Price Target
$101.91
(40.11% upside)
Analyst Consensus: Strong Buy